Modalis Therapeutics Corporation (TYO:4883)

Modalis Therapeutics Cash Flow Statement

Financials in millions JPY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-1,557	-1,316	-2,390	-2,707	-745	-439
Depreciation & Amortization	0.4	-	-	123	77	57
Loss (Gain) From Sale of Assets	-	-	38	997	2	-
Other Operating Activities	73.83	-15	1	1	488	-
Change in Accounts Receivable	-	-	-	-	-	6
Change in Accounts Payable	3.5	-119	49	9	51	-31
Change in Other Net Operating Assets	51.17	18	48	-318	-620	31
Operating Cash Flow	-1,411	-1,432	-2,254	-1,895	-747	-376
Capital Expenditures	-0.58	-	-39	-197	-107	-16
Sale (Purchase) of Intangibles	-	-	-	-	-	-814
Other Investing Activities	-	-	-	12	278	-
Investing Cash Flow	-0.58	-	-39	-185	171	-830
Long-Term Debt Issued	-	694	488	-	-	-
Long-Term Debt Repaid	-	-37	-	-	-	-
Net Debt Issued (Repaid)	657.2	657	488	-	-	-
Issuance of Common Stock	2,798	2,395	735	71	72	2,798
Other Financing Activities	-13.42	-8	-7	-8	-	-21
Financing Cash Flow	3,442	3,044	1,216	63	72	2,777
Foreign Exchange Rate Adjustments	-52.31	79	27	14	17	-6
Miscellaneous Cash Flow Adjustments	5	-	1	-	2	-1
Net Cash Flow	1,983	1,691	-1,049	-2,003	-485	1,564
Free Cash Flow	-1,411	-1,432	-2,293	-2,092	-854	-392
Free Cash Flow Margin	-	-	-	-5230.00%	-85400.00%	-114.62%
Free Cash Flow Per Share	-21.59	-31.05	-74.05	-71.87	-29.70	-14.88
Cash Interest Paid	3.32	3	4	6	-	-
Cash Income Tax Paid	0.95	1	1	1	1	-
Levered Free Cash Flow	-1,412	-890.63	-1,418	-1,402	-787	-1,065
Unlevered Free Cash Flow	-1,409	-885.63	-1,408	-1,399	-786.38	-1,065
Change in Working Capital	54.66	-101	97	-309	-569	6

Source: S&P Global Market Intelligence. Standard template. Financial Sources.